Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status approved; investigational
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343
UNII BZ114NVM5P
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin infection23.11.04.007; 11.01.12.003--
Somnolence19.02.05.003; 17.02.04.006--
Status epilepticus17.12.03.0050.000168%Not Available
Stomatitis07.05.06.0050.000112%
Subarachnoid haemorrhage12.01.10.011; 24.07.04.004; 17.08.01.0100.000112%Not Available
Sudden death08.04.01.003; 02.03.04.013--
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.0020.000224%Not Available
Thrombosis24.01.01.0060.000112%Not Available
Tonsillitis22.07.03.008; 11.01.13.006--Not Available
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Ureteric obstruction20.06.01.005--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine abnormality20.02.01.013--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Ventricular arrhythmia02.03.04.006--
Vertigo17.02.12.002; 04.04.01.0030.000112%
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Multiple sclerosis relapse17.16.01.0030.000280%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.007--Not Available
Ejection fraction decreased13.14.02.003--
Contusion23.03.11.002; 12.01.06.001; 15.03.05.007; 24.07.06.001--
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene